Globus Medical

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Globus Medical, Inc. shares have seen a significant pullback after announcing a $3 billion deal to acquire NuVasive. The company has a strong track record in the spine industry and has been outgrowing its competitors. Despite the uncertainty caused by the deal, Globus has seen solid operating momentum and valuations have become more attractive.

Globus Medical: Almost Having My Back

Globus Medical's (GMED) Precice Bone Transport is a less intrusive treatment that reduces complications for both the patient and the surgeon and is designed for various bone abnormalities.

Globus Medical (GMED) Launches NuVasive's NSO in Global Market

Globus Medical's (GMED) recent deal combines complementary spine and orthopedic solutions, enabling technologies to create one of the industry's most comprehensive, innovative offerings.

Globus Medical (GMED) Completes NuVasive Merger Agreement

—Creates leading global musculoskeletal company— —Robust portfolio well-positioned for long-term growth and continued innovation—

Globus Medical Completes Merger with NuVasive

Goosehead Insurance

Jackson Financial

NexTier Oilfield Solutions Inc

NuVasive

NEW YORK , Aug. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1: Goosehead Insurance Inc. (NASD: GSHD) will replace NuVasive Inc. (NASD: NUVA) in the S&P SmallCap 600. S&P MidCap 400 constituent Globus Medical Inc. (NYSE: GMED) is acquiring NuVasive in a deal expected to close soon pending final conditions.

Goosehead Insurance and Jackson Financial Set to Join S&P SmallCap 600

According to Globus Medical (GMED), the increase in R&D expenses is largely focused on Spine and Enabling Technologies.

Globus Medical (GMED) Q2 Earnings Beat Estimates, Margins Dip

The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Globus Medical (GMED) Q2 Earnings

Globus Medical (GMED) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.60 per share. This compares to earnings of $0.56 per share a year ago.

Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates

AUDUBON, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2023.

Globus Medical Reports Second Quarter 2023 Results

Globus Medical's (GMED) Enabling technology sales improvement is driven by strong performance of its robotic and imaging system.

Globus Medical (GMED) Gains on Innovation, Strategic Deal

MARVEL™ is Globus Medical's second major release this year in the pediatric scoliosis space MARVEL™ is Globus Medical's second major release this year in the pediatric scoliosis space

Globus Medical Announces Launch of the MARVEL™ Growing Rod System, the company's first product designed specifically for early onset scoliosis

Integer Holdings

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Globus Medical (GMED). But which of these two stocks is more attractive to value investors?

ITGR or GMED: Which Is the Better Value Stock Right Now?

Globus Medical's Q1 sales grew by 21% YoY to a record $277m, driven by robust musculoskeletal sales and demand for its robotics offerings. The company's merger with NuVasive, initially met with investor skepticism, is now viewed more positively, as sentiment in the stock continues to improve. Based on earnings power and asset factors, GMED appears undervalued and could trade to $79 per share.

Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy

New product developments and the pending NuVasive acquisition raise optimism about the Globus Medical (GMED) stock.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

AUDUBON, Pa., July 13, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2023 after the market close on Thursday, August 3, 2023. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.

Globus Medical Schedules Second Quarter Earnings Release and Conference Call

Globus Medical (GMED) continues to make significant progress in launching its prone lateral patient positioning system.

Globus Medical (GMED) to Gain From NUVA Merger Amid Margin Woe

Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.

Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod

REFLECT™ is approved through the FDA's Humanitarian Device Exemption pathway REFLECT™ is approved through the FDA's Humanitarian Device Exemption pathway

Globus Medical Announces FDA Approval for its Non-Fusion Scoliosis Correction System, the Latest Advancement for Young Patients with Idiopathic Scoliosis

The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.

Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips

Globus Medical, Inc. (NYSE:GMED ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Brian Kearns - Senior Vice President of Business Development and Investor Relations Dan Scavilla - President and CEO Keith Pfeil - Senior Vice President and Chief Financial Officer Conference Call Participants Mike Miksic - Barclays Shagun Singh - RBC David Saxon - Needham & Co Sam Dane - BTIG Kyle Rose - Canaccord Vik Chopra - Wells Fargo Operator Welcome to Globus Medical's First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

Globus Medical, Inc. (GMED) Q1 2023 Earnings Call Transcript

Globus Medical (GMED) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.42 per share a year ago.

Globus Medical (GMED) Surpasses Q1 Earnings and Revenue Estimates

AUDUBON, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2023.

Globus Medical Reports First Quarter 2023 Results

Globus Medical caught headlines after announcing the NuVasive merger. Investors have wiped out considerable equity post-announcement, but the worst may be now priced in.

Globus Medical: Still Very Attractive After NuVasive Selloff

AUDUBON, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that at the special meeting of shareholders held earlier today its shareholders voted to approve the issuance of shares of Globus Medical Class A common stock in connection with the proposed merger with NuVasive (NASDAQ: NUVA). As previously announced, under the terms of the merger agreement, Globus Medical will issue 0.75 of a share of Globus Medical Class A common stock in exchange for each share of NuVasive common stock owned at the closing of the transaction.

Globus Medical Shareholders Approve Share Issuance for Merger with NuVasive

SAN DIEGO , April 27, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that at the special meeting of shareholders held earlier today, its shareholders voted to approve the adoption of the Company's merger agreement with Globus Medical (NYSE: GMED). As previously announced, under the terms of the merger agreement, NuVasive shareholders will receive 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive common stock owned at the closing of the transaction.

News for Globus Medical Stock (GMED)